Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Biochemical Pharmacology|March 9, 2010
Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cellsJin-Jian Lu, Ling-Hua Meng, Uma T Shankavaram, et al.
Cancer Letters|October 24, 2021
Repressing MYC by targeting BET synergizes with selective inhibition of PI3Kα against B cell lymphomaZi-Qi Chen, Zhe-Rui Cao, Yi Wang, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 24, 2013
DW09849, a selective phosphatidylinositol 3-kinase (PI3K) inhibitor, prevents PI3K signaling and preferentially inhibits proliferation of cells containing the oncogenic mutation p110α (H1047R)Jia-li Liu, Guo-rui Gao, Xi Zhang, et al.
Acta Pharmacologica Sinica|April 18, 2017
Docking-based structural splicing and reassembly strategy to develop novel deazapurine derivatives as potent B-Raf<sup>V600E</sup> inhibitorsGui-Min Wang, Xiang Wang, Jian-Ming Zhu, et al.
Journal for Immunotherapy of Cancer|August 10, 2021
PI3Kα inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8<sup>+</sup>T cells and promoting fatty acid metabolismPu Sun, Xi Zhang, Rong-Jing Wang, et al.
Plos One|March 19, 2009
S9, a novel anticancer agent, exerts its anti-proliferative activity by interfering with both PI3K-Akt-mTOR signaling and microtubule cytoskeletonChao Zhang, Na Yang, Chun-Hao Yang, et al.
Cell Death & Disease|January 15, 2021
Adaptive resistance to PI3Kα-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cellsYu-Xiang Wang, Xu Zhang, Qing-Yang Ma, et al.
STAR Protocols|September 27, 2023
Protocol for PPP1R15A-inhibited mouse model establishment with subcutaneous B16F1 tumor and single-cell analysisRongjing Wang, Minghui Wang, Siyu Pei, et al.
Iscience|January 31, 2023
Single-cell RNA sequencing reveals the suppressive effect of PPP1R15A inhibitor Sephin1 in antitumor immunityRongjing Wang, Yuchao Zhang, Shiwei Guo, et al.
European Journal of Medicinal Chemistry|October 28, 2020
Identification of methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate (CYH33) as an orally bioavailable, highly potent, PI3K alpha inhibitor for the treatment of advanced solid tumorsHao-Yue Xiang, Xiang Wang, Yan-Hong Chen, et al.
Pageof 7